Skip to main content
Top

10-09-2018 | Chronic myeloid leukemia | Article

Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?

Journal: Leukemia

Authors: Nazanin Aghel, Diego Hernan Delgado, Jeffrey Howard Lipton

Publisher: Nature Publishing Group UK

Abstract

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML). Although these treatments have changed the natural course of CML and many other cancers, they may cause cardiovascular and/or metabolic complications. In this review, we discuss how overlooking the main drivers of cardiovascular events (CVEs) and lack of standard definitions for cardiovascular adverse events might have affected these event rates in CML trials. Methodological limitations that affect the available data are discussed, with an emphasis on the future direction of cardiovascular safety research in trials of investigational drugs in cancer treatment.
Literature
1.
Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27325849.CrossRef
2.
Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210–8. http://​jco.​ascopubs.​org/​cgi/​doi/​10.​1200/​JCO.​2015.​62.​4718.CrossRef
3.
Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457–67. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​27732808.CrossRef
4.
Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O, Moslehi J. Vascular and metabolic implications of novel targeted cancer therapies. J Am Coll Cardiol. 2015;66:1160–78. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​26337996.CrossRef
5.
Levato L, Cantaffa R, Kropp MG, Magro D, Piro E, Molica S. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in chronic myeloid leukemia: a single institution study. Eur J Haematol. 2013;90:531–2. http://​doi.​wiley.​com/​10.​1111/​ejh.​12096.CrossRef
6.
Kim TD, le Coutre P, Schwarz M, Grille P, Levitin M, Fateh-Moghadam S, et al. Clinical cardiac safety profile of nilotinib. Haematologica. 2012;97:883–9. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22271904.CrossRef
7.
8.
Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–96. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​24180494.CrossRef
9.
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:612–21. http://​linkinghub.​elsevier.​com/​retrieve/​pii/​S147020451600080​2.CrossRef
10.
Johnson CB, Davis MK, Law A, Sulpher J. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol. 2016;32:900–7. http://​linkinghub.​elsevier.​com/​retrieve/​pii/​S0828282X1630052​6.CrossRef
12.
Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, et al. ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials. J Am Coll Cardiol. 2015;66:403–69. http://​linkinghub.​elsevier.​com/​retrieve/​pii/​S073510971407484​1.CrossRef
13.
Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, et al.Cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137:961–72. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​29483172.CrossRef
14.
Pocock SJ, Clayton TC, Stone GW. Design of major randomized trials. J Am Coll Cardiol. 2015;66:2757–66. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​26700838.CrossRef
15.
Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. PLoS One. 2012;7:e41174.CrossRef
16.
Giles FJ, Mauro MJ, Hong F, Ortmann C-E, McNeill C, Woodman RC, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia [Internet]. 2013;27:1310–5. http://​www.​nature.​com/​doifinder/​10.​1038/​leu.​2013.​69.CrossRef
17.
Kim TD, Rea D, Schwarz M, Grille P, Nicolini FE, Rosti G, et al. Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia. 2013;27:1316–21. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23459449.CrossRef
18.
Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, et al. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014;32:83–9. http://​ascopubs.​org/​doi/​10.​1200/​JCO.​2013.​52.​2219.CrossRef
19.
Vaduganathan M, Prasad V. Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?. Eur J Heart Fail. 2016;18:128–32. http://​doi.​wiley.​com/​10.​1002/​ejhf.​457.CrossRef
20.
Fda. Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. http://​www.​fda.​gov/​cder/​guidance/​index.​htm.
21.
Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699–708. http://​www.​nejm.​org/​doi/​10.​1056/​NEJMoa1105819.CrossRef
22.
D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117:743–53. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​18212285.CrossRef
23.
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (London, England). 2004;364:937–52. http://​linkinghub.​elsevier.​com/​retrieve/​pii/​S014067360417018​9.CrossRef
24.
The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988;41:105–14. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​3335877.
25.
Sigurdsson E, Thorgeirsson G, Sigvaldason H, Sigfusson N. Prevalence of coronary heart disease in Icelandic men 1968–1986. The Reykjavik Study. Eur Heart J. 1993;14:584–91. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​8508850.CrossRef
26.
Liu J, Fox CS, Hickson D, Sarpong D, Ekunwe L, May WD, et al. Pericardial adipose tissue, atherosclerosis, and cardiovascular disease risk factors: the Jackson Heart Study. Diabetes Care. 2010;33:1635–9. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​20413524.CrossRef
27.
Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103:1347–8. https://​academic.​oup.​com/​jnci/​article-lookup/​doi/​10.​1093/​jnci/​djr292.CrossRef
28.
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim D-W, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–54. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​26837842.CrossRef
29.
Aghel N, Lipton JH, Atenafu EG, Kim DDH, Delgado DH. Cardiovascular events after exposure to nilotinib in chronic myeloid leukemia: long-term follow-up. Clin Lymphoma Myeloma Leuk. 2017;17:870–878.e1.CrossRef
30.
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics’2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–603.CrossRef
31.
Steg PG, Bhatt DL, Wilson PWF, D’Agostino R, Ohman EM, Röther J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297:1197. http://​jama.​jamanetwork.​com/​article.​aspx?​doi=​10.​1001/​jama.​297.​11.​1197.CrossRef
32.
Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​20805624.CrossRef
33.
Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163–70. https://​academic.​oup.​com/​eurheartj/​article-lookup/​doi/​10.​1093/​eurheartj/​ehu505 CrossRef
34.
Abu-Assi E, López-López A, González-Salvado V, Redondo-Diéguez A, Peña-Gil C, Bouzas-Cruz N, et al. The risk of cardiovascular events after an acute coronary event remains high, especially during the first year, despite revascularization. Rev Esp Cardiol (Engl Ed). 2016;69:11–8. http://​linkinghub.​elsevier.​com/​retrieve/​pii/​S188558571500270​4 CrossRef
35.
Jabbour E, Makenbaeva D, Lingohr-Smith M, Lin J. Use of real-world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on national comprehensive network treatment guidelines. Clin Lymphoma Myeloma Leuk. 2015;15:797–802.e1. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​26603185.CrossRef
36.
Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382:1329–40. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23915883.CrossRef
37.
Hiatt WR, Goldstone J, Smith SC, McDermott M, Moneta G, Oka R, et al. Atherosclerotic Peripheral Vascular Disease Symposium II: nomenclature for vascular diseases. Circulation. 2008;118:2826–9. http://​circ.​ahajournals.​org/​cgi/​doi/​10.​1161/​CIRCULATIONAHA.​108.​191171.CrossRef
38.
Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509–26. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25908725.CrossRef
39.
Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110:738–43. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​15262830.CrossRef
40.
Poredos P, Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology. 2007;58:309–15. http://​ang.​sagepub.​com/​cgi/​doi/​10.​1177/​0003319707302494​.CrossRef
41.
Subherwal S, Patel MR, Chiswell K, Tidemann-Miller BA, Jones WS, Conte MS, et al. Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database. Circulation. 2014;130:1812–9. http://​circ.​ahajournals.​org/​cgi/​doi/​10.​1161/​CIRCULATIONAHA.​114.​011021.CrossRef
42.
Howard DPJ, Banerjee A, Fairhead JF, Hands L, Silver LE, Rothwell PM, et al. Population-based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events: implications for prevention. Circulation. 2015;132:1805–15. http://​circ.​ahajournals.​org/​lookup/​doi/​10.​1161/​CIRCULATIONAHA.​115.​016424.CrossRef
43.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation. 2012;126:2020–35. http://​circ.​ahajournals.​org/​cgi/​doi/​10.​1161/​CIR.​0b013e31826e1058​.CrossRef
44.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27. http://​www.​nejm.​org/​doi/​10.​1056/​NEJMoa1609324%0A. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28273028.CrossRef
45.
Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333–40. http://​ascopubs.​org/​doi/​10.​1200/​JCO.​2015.​64.​8899.CrossRef
46.
Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. Cancer. 2009;115:4136–47. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​19536906.CrossRef
47.
Wang J, Shen Z-X, Saglio G, Jin J, Huang H, Hu Y, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015;125:2771–8. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​25766724.CrossRef
48.
Hughes TP, Munhoz E, Aurelio Salvino M, Ong TC, Elhaddad A, Shortt J, et al. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. Br J Haematol. 2017;179:219–28. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​28699641.CrossRef
49.
Cortes JE, De Souza CA, Ayala M, Lopez JL, Bullorsky E, Shah S, et al. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016;3:e581–91. http://​linkinghub.​elsevier.​com/​retrieve/​pii/​S235230261630167​3.CrossRef
50.
Cortes JE, Kim D-W, Kantarjian HM, Brümmendorf TH, Dyagil I, Griskevicius L, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486–92. http://​ascopubs.​org/​doi/​10.​1200/​JCO.​2011.​38.​7522.CrossRef
51.
Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim D-W, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2017;36:231–237. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​29091516.CrossRef
52.
Aichberger KJ, Herndlhofer S, Schernthaner G-H, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86:533–9.CrossRef
53.
Quintás-Cardama A, Kantarjian H, Cortes J. Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk. 2012;12:337–40. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​22633167.CrossRef
54.
Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075–88. http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​23190221.CrossRef